{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:18:59Z","timestamp":1787678339000,"version":"build-2784847793"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018542","name":"Natural Science Foundation of Sichuan Province","doi-asserted-by":"publisher","award":["2025ZNSFSC0766"],"award-info":[{"award-number":["2025ZNSFSC0766"]}],"id":[{"id":"10.13039\/501100018542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82370998"],"award-info":[{"award-number":["82370998"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bioorg.2026.110195","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T23:24:03Z","timestamp":1782861843000},"page":"110195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Structure-guided modulation of the IL-4\/IL-4R\u03b1 interface: molecular recognition, therapeutic antibodies, and small-molecule opportunities"],"prefix":"10.1016","volume":"180","author":[{"given":"Ruijie","family":"Jiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisha","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkang","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2026.110195_bb0005","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/acs.jmedchem.2c01957","article-title":"Perspective for discovery of small molecule IL-6 inhibitors through study of structure\u2013activity relationships and molecular docking","volume":"66","author":"Nada","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0010","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41573-023-00746-x","article-title":"Strategies to therapeutically modulate cytokine action","volume":"22","author":"Leonard","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110195_bb0015","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/0008-8749(74)90066-5","article-title":"Commentary. Similarities of T cell function in cell-mediated immunity and antibody production","volume":"12","author":"Cohen","year":"1974","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0020","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1378\/chest.117.4.1162","article-title":"Anti-inflammatory cytokines","volume":"117","author":"Opal","year":"2000","journal-title":"Chest"},{"key":"10.1016\/j.bioorg.2026.110195_bb0025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/imr.13230","article-title":"Engineering the IL-4\/IL-13 axis for targeted immune modulation","volume":"320","author":"Bernstein","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioorg.2026.110195_bb0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-immunol-101921-041206","article-title":"IL-4 and IL-13: regulators and effectors of wound repair","volume":"41","author":"Allen","year":"2023","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0035","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1097\/CM9.0000000000001990","article-title":"Characteristics, phenotypes, mechanisms and management of severe asthma","volume":"135","author":"Chung","year":"2022","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bioorg.2026.110195_bb0040","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110195_bb0045","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.3390\/cells10113000","article-title":"Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis","volume":"10","author":"Iwaszko","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2026.110195_bb0050","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110195_bb0055","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1038\/s41467-021-22834-5","article-title":"Dual vaccination against IL-4 and IL-13 protects against chronic allergic asthma in mice","volume":"12","author":"Conde","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110195_bb0060","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1084\/jem.155.3.914","article-title":"Identification of a T cell-derived b cell growth factor distinct from interleukin 2","volume":"155","author":"Howard","year":"1982","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0065","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.72923","article-title":"IL-4 and helminth infection downregulate MINCLE-dependent macrophage response to mycobacteria and Th17 adjuvanticity","volume":"12","author":"Schick","year":"2023","journal-title":"eLife"},{"key":"10.1016\/j.bioorg.2026.110195_bb0070","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood.2022017326","article-title":"IL-13\/IL-4 signaling contributes to fibrotic progression of the myeloproliferative neoplasms","volume":"140","author":"Melo-Cardenas","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bioorg.2026.110195_bb0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12016-020-08797-3","article-title":"COVID-19 and asthma: reflection during the pandemic","volume":"59","author":"Liu","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0080","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/14728214.2015.1050377","article-title":"Anti-IL-4\/\u221213 based therapy in asthma","volume":"20","author":"Walsh","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/j.bioorg.2026.110195_bb0085","first-page":"925","article-title":"IL-4 and IL-13 inhibition in atopic dermatitis","volume":"15","author":"Matsunaga","year":"2016","journal-title":"J. Drugs Dermatol. JDD"},{"key":"10.1016\/j.bioorg.2026.110195_bb0090","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/acschembio.0c00615","article-title":"A small-molecule inhibitor to the cytokine Interleukin-4","volume":"15","author":"Quinnell","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0095","doi-asserted-by":"crossref","first-page":"10026","DOI":"10.1074\/jbc.RA117.000567","article-title":"Small molecule targeting of the STAT5\/6 Src homology 2 (SH2) domains to inhibit allergic airway disease","volume":"293","author":"Knight","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0100","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jaip.2023.03.011","article-title":"Biologic versus small molecule therapy for treating moderate to severe atopic dermatitis: clinical considerations","volume":"11","author":"Butala","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.bioorg.2026.110195_bb0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1177\/1753425916659702","article-title":"Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells","volume":"22","author":"Zhao","year":"2016","journal-title":"Innate Immun."},{"key":"10.1016\/j.bioorg.2026.110195_bb0110","first-page":"1431","article-title":"Advances of monoclonal antibodies and analysis of marketed antibody drugs","volume":"40","author":"Gu","year":"2024","journal-title":"Sheng Wu Gong Cheng Xue Bao (Chin. J. Biotechnol.)"},{"key":"10.1016\/j.bioorg.2026.110195_bb0115","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.coph.2012.08.001","article-title":"Monoclonal antibody therapeutics: history and future","volume":"12","author":"Buss","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ejmech.2016.09.023","article-title":"Structure-activity relationship (SAR) study and design strategies of nitrogen-containing heterocyclic moieties for their anticancer activities","volume":"125","author":"Akhtar","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111581","article-title":"Small molecule modulators targeting protein kinase CK1 and CK2","volume":"181","author":"Qiao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0130","doi-asserted-by":"crossref","first-page":"212","DOI":"10.3389\/fphar.2019.00212","article-title":"Targeting cytokine Signaling and lymphocyte traffic via small molecules in inflammatory bowel disease: JAK inhibitors and S1PR agonists","volume":"10","author":"P\u00e9rez-Jeldres","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0135","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev.immunol.16.1.293","article-title":"JAKS AND STATS: Biological implications","volume":"16","author":"Leonard","year":"1998","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0140","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1126\/science.8266078","article-title":"Interleukin-2 receptor \u03b3 chain: a functional component of the Interleukin-4 receptor","volume":"262","author":"Russell","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110195_bb0145","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1146\/annurev.immunol.17.1.701","article-title":"The IL-4 receptor: signaling mechanisms and biologic functions","volume":"17","author":"Nelms","year":"1999","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0150","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0092-8674(93)90167-O","article-title":"Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans","volume":"73","author":"Noguchi","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110195_bb0155","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fimmu.2018.00888","article-title":"Tuning the cytokine responses: an update on interleukin (IL)-4 and IL-13 receptor complexes","volume":"9","author":"Junttila","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0160","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S1074-7613(00)80439-2","article-title":"Stat6 is required for mediating responses to IL-4 and for the development of Th2 cells","volume":"4","author":"Kaplan","year":"1996","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.110195_bb0170","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fimmu.2020.00509","article-title":"Regulatory T cells beyond autoimmunity: from pregnancy to Cancer and cardiovascular disease","volume":"11","author":"Martini","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0175","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1006\/smim.1998.0141","article-title":"The serum mannose-binding protein and the macrophage mannose receptor are pattern recognition molecules that link innate and adaptive immunity","volume":"10","author":"Fraser","year":"1998","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0180","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/acr.23549","article-title":"Levels of cytokines and MicroRNAs in individuals with asymptomatic hyperuricemia and ultrasonographic findings of gout: a bench-to-bedside approach","volume":"70","author":"Estevez-Garcia","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.bioorg.2026.110195_bb0185","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.jaci.2022.12.802","article-title":"STAT6 gain-of-function variant exacerbates multiple allergic symptoms","volume":"151","author":"Takeuchi","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0190","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0195","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.202306-1102LE","article-title":"Effects of dupilumab on mucus plugging and ventilation defects in patients with moderate-to-severe asthma: a randomized, double-blind, placebo-controlled trial","volume":"208","author":"Svenningsen","year":"2023","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0200","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J. Hematol. Oncol. J. Hematol. Oncol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.156091","article-title":"IL-4 and IL-13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline","volume":"162","author":"Scott","year":"2023","journal-title":"Cytokine"},{"key":"10.1016\/j.bioorg.2026.110195_bb0210","first-page":"835","article-title":"The IL-4, IL-13 and IL-31 pathways in atopic dermatitis, expert rev","volume":"17","author":"Dubin","year":"2021","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0215","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cyto.2015.05.014","article-title":"IL-4 and IL-13 signaling in allergic airway disease","volume":"75","author":"Gour","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.bioorg.2026.110195_bb0220","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.jaci.2022.06.012","article-title":"Modulation of IL-4\/IL-13 cytokine signaling in the context of allergic disease","volume":"150","author":"Shankar","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0225","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1086\/344188","article-title":"Guidelines for the prevention of intravascular catheter-related infections","volume":"35","author":"O\u2019Grady","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.bioorg.2026.110195_bb0230","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/j.immuni.2019.03.018","article-title":"The cytokines of asthma","volume":"50","author":"Lambrecht","year":"2019","journal-title":"Immunity"},{"key":"10.1016\/j.bioorg.2026.110195_bb0235","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.bioorg.2026.110195_bb0240","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","article-title":"Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis","volume":"12","author":"Wang","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bioorg.2026.110195_bb0245","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt signal transduction for cancer therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bioorg.2026.110195_bb0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.18176\/jiaci.0823","article-title":"Eosinophilia induced by blocking the IL-4\/IL-13 pathway: potential mechanisms and clinical outcomes","volume":"32","author":"Olaguibel","year":"2022","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.bioorg.2026.110195_bb0255","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/1744666X.2017.1298443","article-title":"Commonality of the IL-4\/IL-13 pathway in atopic diseases","volume":"13","author":"Gandhi","year":"2017","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0260","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41572-020-00227-0","article-title":"Allergic rhinitis","volume":"6","author":"Bousquet","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.bioorg.2026.110195_bb0265","doi-asserted-by":"crossref","DOI":"10.1111\/imr.13380","article-title":"Therapeutic monoclonal antibodies in allergy: targeting IgE, cytokine, and alarmin pathways","author":"Eggel","year":"2024","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bioorg.2026.110195_bb0270","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.iac.2020.06.001","article-title":"Biologics for the treatment of allergic rhinitis, chronic rhinosinusitis, and nasal polyposis","volume":"40","author":"Eschenbacher","year":"2020","journal-title":"Immunol. Allergy Clin. N. Am."},{"key":"10.1016\/j.bioorg.2026.110195_bb0275","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-017-0777-2","article-title":"Targeting the PGD2\/CRTH2\/DP1 Signaling pathway in asthma and allergic disease: current status and future perspectives","volume":"77","author":"Kupczyk","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.bioorg.2026.110195_bb0280","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1208\/s12248-014-9687-3","article-title":"Strategic approaches to optimizing peptide ADME properties","volume":"17","author":"Di","year":"2015","journal-title":"AAPS J."},{"key":"10.1016\/j.bioorg.2026.110195_bb0285","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2020.1785868","article-title":"PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD","volume":"14","author":"Gilardi","year":"2020","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0290","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra2023911","article-title":"Atopic dermatitis","volume":"384","author":"St\u00e4nder","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0295","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.bioorg.2026.110195_bb0300","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0305","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110195_bb0310","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106552","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2023 update","volume":"187","author":"Roskoski","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2026.110195_bb0320","article-title":"Advances in the diagnosis and management of IgG4 related disease","volume":"369","author":"L.","year":"2020","journal-title":"BMJ"},{"key":"10.1016\/j.bioorg.2026.110195_bb0325","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41573-021-00266-6","article-title":"Atopic dermatitis: an expanding therapeutic pipeline for a complex disease","volume":"21","author":"Bieber","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bioorg.2026.110195_bb0330","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003026","article-title":"IgG4-related disease administered dupilumab: case series and review of the literature","volume":"9","author":"Kanda","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.bioorg.2026.110195_bb0335","article-title":"Glucocorticoids in the treatment of IgG4-related disease-prospects for new international treatment guidelines","volume":"33","author":"Y.","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0340","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1146\/annurev-med-050219-034449","article-title":"Clinical perspectives on IgG4-related disease and its classification","volume":"73","author":"Katz","year":"2022","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0345","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00296-023-05510-3","article-title":"An overlapping case of IgG4-related disease and systemic lupus erythematosus treated with belimumab: a case-based review","volume":"44","author":"Iwamoto","year":"2024","journal-title":"Rheumatol. Int."},{"key":"10.1016\/j.bioorg.2026.110195_bb0350","doi-asserted-by":"crossref","first-page":"11315","DOI":"10.1038\/s41598-017-11803-y","article-title":"IL-4 enhances IL-10 production in Th1 cells: implications for Th1 and Th2 regulation","volume":"7","author":"Mitchell","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110195_bb0355","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41584-018-0109-2","article-title":"Anti-inflammatory and immune-regulatory cytokines in rheumatoid arthritis","volume":"15","author":"Chen","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0360","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.867260","article-title":"The role of M1\/M2 macrophage polarization in rheumatoid arthritis synovitis","volume":"13","author":"Cutolo","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0365","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1146\/annurev-immunol-032712-095906","article-title":"Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease","volume":"31","author":"Van Dyken","year":"2013","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2023.108348","article-title":"Interleukin-4 as a therapeutic target","volume":"242","author":"G\u00e4rtner","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2026.110195_bb0375","article-title":"Interleukin-4 protects dopaminergic neurons in vitro but is dispensable for MPTP-induced neurodegeneration in vivo","volume":"10","author":"H.","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.bioorg.2026.110195_bb0380","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1471-4159.2006.04172.x","article-title":"Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia","volume":"99","author":"Zhao","year":"2006","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0385","doi-asserted-by":"crossref","first-page":"4192","DOI":"10.1021\/jm9005093","article-title":"Design, synthesis, biological evaluation, and structure-activity relationship (SAR) discussion of dipeptidyl boronate proteasome inhibitors, part I: comprehensive understanding of the SAR of alpha-amino acid boronates","volume":"52","author":"Zhu","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0390","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.3390\/ijms20184331","article-title":"Molecular docking: shifting paradigms in drug discovery","volume":"20","author":"Pinzi","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2026.110195_bb0395","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cytogfr.2016.04.002","article-title":"Interleukin-4 receptor signaling and its binding mechanism: a therapeutic insight from inhibitors tool box","volume":"32","author":"Ul-Haq","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.bioorg.2026.110195_bb0400","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0167-4889(02)00318-X","article-title":"Structure, binding, and antagonists in the IL-4\/IL-13 receptor system","volume":"1592","author":"Mueller","year":"2002","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bioorg.2026.110195_bb0405","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ijbiomac.2018.10.204","article-title":"Characterization of cryptic allosteric site at IL-4R\u03b1: new paradigm towards IL-4\/IL-4R inhibition","volume":"123","author":"Naz","year":"2019","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0410","first-page":"1286","article-title":"Pitrakinra, a dual IL-4\/IL-13 antagonist for the potential treatment of asthma and eczema","volume":"11","author":"Antoniu","year":"2010","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.bioorg.2026.110195_bb0415","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(07)61600-6","article-title":"Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies","volume":"370","author":"Wenzel","year":"2007","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bioorg.2026.110195_bb0420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jaci.2014.12.1871","article-title":"Asthma phenotypes and the use of biologic medications in asthma and allergic disease: the next steps toward personalized care","volume":"135","author":"Fajt","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0425","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2010.08.042","article-title":"Use of the asthma control questionnaire to predict future risk of asthma exacerbation","volume":"127","author":"Meltzer","year":"2011","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0430","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.200909-1448OC","article-title":"A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma","volume":"181","author":"Corren","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0435","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.bioorg.2026.110195_bb0440","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1056\/NEJMoa1704064","article-title":"Tezepelumab in adults with uncontrolled asthma","volume":"377","author":"Corren","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0445","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1126\/science.1213256","article-title":"A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield","volume":"334","author":"Pejchal","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110195_bb0455","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jaci.2018.08.022","article-title":"Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis","volume":"143","author":"Guttman-Yassky","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0460","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.jaad.2017.12.022","article-title":"Dupilumab: a review of its use in the treatment of atopic dermatitis","volume":"78","author":"Gooderham","year":"2018","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0465","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/CM9.0000000000002747","article-title":"Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: a multicenter, randomized, double-blind, placebo-controlled phase 2b trial","volume":"137","author":"Zhao","year":"2023","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.bioorg.2026.110195_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110721","article-title":"Stapokibart (CM310) targets IL-4R\u03b1 for the treatment of type 2 inflammation","volume":"27","author":"Liu","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.bioorg.2026.110195_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102076","article-title":"Efficacy and safety of CM310 in severe eosinophilic chronic rhinosinusitis with nasal polyps (CROWNS-1): a multicentre, randomised, double-blind, placebo-controlled phase 2 clinical trial","volume":"61","author":"Zhang","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.bioorg.2026.110195_bb0480","doi-asserted-by":"crossref","first-page":"12411","DOI":"10.1038\/s41598-023-39311-2","article-title":"Preclinical immunological characterization of rademikibart (CBP-201), a next-generation human monoclonal antibody targeting IL-4R\u03b1, for the treatment of Th2 inflammatory diseases","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110195_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2023.11.924","article-title":"Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4R\u03b1, in adults with moderate to severe atopic dermatitis: a phase 2 randomized trial (CBP-201-WW001)","volume":"153","author":"Silverberg","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0490","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1111\/cts.13656","article-title":"Rademikibart (CBP-201), a next-generation monoclonal antibody targeting human IL-4R\u03b1: two phase I randomized trials, in healthy individuals and patients with atopic dermatitis","volume":"16","author":"Wang","year":"2023","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.bioorg.2026.110195_bb0495","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s13555-023-01010-1","article-title":"Safety, pharmacokinetics and preliminary efficacy of IL4-r\u03b1 monoclonal antibody AK120 in both healthy and atopic dermatitis subjects: a phase I, randomized, two-part, double-blind, placebo-controlled, dose-escalation, first-in-human clinical study","volume":"13","author":"Wynne","year":"2023","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.bioorg.2026.110195_bb0500","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.jaci.2024.05.027","article-title":"A novel inhalable nanobody targeting IL-4R\u03b1 for the treatment of asthma","volume":"154","author":"Zhu","year":"2024","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bioorg.2026.110195_bb0505","article-title":"Eblasakimab, a novel IL-13 receptor alpha 1 monoclonal antibody, blocks STAT6 phosphorylation with low dose in human volunteers","volume":"253","author":"Cevikbas","year":"2023","journal-title":"Clin. Immunol. Orlando Fla"},{"key":"10.1016\/j.bioorg.2026.110195_bb0510","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/pharmaceutics15020568","article-title":"Targeting interleukin 13 for the treatment of atopic dermatitis","volume":"15","author":"Lytvyn","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bioorg.2026.110195_bb0515","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40259-024-00685-y","article-title":"Eblasakimab, an anti-IL-13R\u03b11 antibody, reduces atopy-associated serum biomarkers in moderate-to-severe atopic dermatitis","volume":"38","author":"Cevikbas","year":"2024","journal-title":"BioDrugs"},{"key":"10.1016\/j.bioorg.2026.110195_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/j.xjidi.2024.100258","article-title":"A bispecific, tetravalent antibody targeting inflammatory and pruritogenic pathways in atopic dermatitis","volume":"4","author":"Tietz","year":"2024","journal-title":"JID Innov."},{"key":"10.1016\/j.bioorg.2026.110195_bb0525","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.3390\/jcm13144001","article-title":"A comprehensive review of biologics in phase III and IV clinical trials for atopic dermatitis","volume":"13","author":"Walig\u00f3ra-Dziwak","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0530","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nrc1913","article-title":"Comparing antibody and small-molecule therapies for cancer","volume":"6","author":"Imai","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.bioorg.2026.110195_bb0535","doi-asserted-by":"crossref","first-page":"685","DOI":"10.7164\/antibiotics.55.685","article-title":"TMC-256A1 and C1, new inhibitors of IL-4 signal transduction produced by aspergillus Niger var niger TC 1629","volume":"55","author":"Sakurai","year":"2002","journal-title":"J. Antibiot. (Tokyo)"},{"key":"10.1016\/j.bioorg.2026.110195_bb0540","doi-asserted-by":"crossref","first-page":"W159","DOI":"10.1093\/nar\/gkac394","article-title":"CB-Dock2: improved protein-ligand blind docking by integrating cavity detection, docking and homologous template fitting","volume":"50","author":"Liu","year":"2022","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2026.110195_bb0545","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.freeradbiomed.2019.03.024","article-title":"Suplatast tosilate reduces radiation-induced lung injury in mice through suppression of oxidative stress","volume":"136","author":"Izumi","year":"2019","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2022.105410","article-title":"Caffeoyl malic acid is a potential dual inhibitor targeting TNF\u03b1\/IL-4 evaluated by a combination strategy of network analysis-deep learning-molecular simulation","volume":"145","author":"Wang","year":"2022","journal-title":"Comput. Biol. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0555","doi-asserted-by":"crossref","first-page":"3950","DOI":"10.1016\/j.cell.2022.09.019","article-title":"State-selective modulation of heterotrimeric g\u03b1s signaling with macrocyclic peptides","volume":"185","author":"Dai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2026.110195_bb0560","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1126\/science.adk1687","article-title":"Expansive discovery of chemically diverse structured macrocyclic oligoamides","volume":"384","author":"Salveson","year":"2024","journal-title":"Science"},{"key":"10.1016\/j.bioorg.2026.110195_bb0565","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1161\/CIRCULATIONAHA.122.063372","article-title":"Orally bioavailable macrocyclic peptide that inhibits binding of PCSK9 to the low density lipoprotein receptor","volume":"148","author":"Johns","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.bioorg.2026.110195_bb0570","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1001\/jama.2025.20620","article-title":"Efficacy and safety of oral PCSK9 inhibitor enlicitide in adults with heterozygous familial hypercholesterolemia","volume":"335","author":"Ballantyne","year":"2026","journal-title":"JAMA"},{"key":"10.1016\/j.bioorg.2026.110195_bb0575","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/S0140-6736(25)01576-4","article-title":"Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials","volume":"406","author":"Gold","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bioorg.2026.110195_bb0580","doi-asserted-by":"crossref","first-page":"17515","DOI":"10.1038\/s41598-024-67371-5","article-title":"JNJ-77242113, a highly potent, selective peptide targeting the IL-23 receptor, provides robust IL-23 pathway inhibition upon oral dosing in rats and humans","volume":"14","author":"Fourie","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110195_bb0585","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1056\/NEJMoa2308713","article-title":"An oral interleukin-23\u2013receptor antagonist peptide for plaque psoriasis","volume":"390","author":"Bissonnette","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2026.110195_bb0590","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1021\/acs.jmedchem.5b01693","article-title":"A binding site on IL-17A for inhibitory macrocycles revealed by hydrogen\/deuterium exchange mass spectrometry","volume":"59","author":"Espada","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0595","article-title":"Binding site elucidation and structure guided design of macrocyclic IL-17A antagonists","volume":"6","author":"Liu","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2026.110195_bb0600","doi-asserted-by":"crossref","first-page":"8354","DOI":"10.1021\/acs.jmedchem.1c00327","article-title":"Macrolide inspired macrocycles as modulators of the IL-17A\/IL-17RA interaction","volume":"64","author":"Ko\u0161trun","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2026.110195_bb0605","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1038\/s41467-025-56601-7","article-title":"Discovery of selective low molecular weight interleukin-36 receptor antagonists by encoded library technologies","volume":"16","author":"Velcicky","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bioorg.2026.110195_bb0610","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cell.2007.12.030","article-title":"Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4\/13 system","volume":"132","author":"LaPorte","year":"2008","journal-title":"Cell"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007315?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206826007315?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:28:58Z","timestamp":1787675338000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206826007315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":120,"alternative-id":["S0045206826007315"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110195","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-guided modulation of the IL-4\/IL-4R\u03b1 interface: molecular recognition, therapeutic antibodies, and small-molecule opportunities","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2026.110195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110195"}}